Edwards Lifesciences AFS and Trading Securities - Unrealized Loss Position (>=12 Months) decreased by 23.8% to $53.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 63.7%, from $146.40M to $53.20M. This is a positive signal — lower values indicate better performance for this metric.
Higher values suggest a significant portion of the portfolio is subject to prolonged market value depreciation.
The aggregate fair value of available-for-sale and trading debt securities that have been in an unrealized loss position...
Standard metric for assessing long-term investment portfolio health across the banking sector.
afs_debt_securities_unrealized_loss_12m_plus| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $58.80M | $81.60M | $393.20M | $1.11B | $1.19B | $1.08B | $953.40M | $843.70M | $622.10M | $432.70M | $295.00M | $214.20M | $146.40M | $116.90M | $90.40M | $69.80M | $53.20M |
| QoQ Change | — | — | — | — | +38.8% | +381.9% | +182.7% | +7.2% | -9.2% | -11.9% | -11.5% | -26.3% | -30.4% | -31.8% | -27.4% | -31.7% | -20.2% | -22.7% | -22.8% | -23.8% |
| YoY Change | — | — | — | — | — | — | — | >999% | >999% | +142.5% | -24.1% | -47.8% | -60.0% | -69.1% | -74.6% | -76.5% | -73.0% | -69.4% | -67.4% | -63.7% |